Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Neurol Neurosurg Psychiatry ; 91(10): 1076-1084, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32651251

RESUMEN

OBJECTIVE: Antibodies against contactin-associated protein-like 2 (CASPR2-Abs) have been described in acquired neuromyotonia, limbic encephalitis (LE) and Morvan syndrome (MoS). However, it is unknown whether these constitute one sole spectrum of diseases with the same immunopathogenesis or three distinct entities with different mechanisms. METHODS: A cluster analysis of neurological symptoms was performed in a retrospective cohort of 56 CASPR2-Abs patients. In parallel, immunological features and human leucocyte antigen (HLA) were studied. RESULTS: Cluster analysis distinguished patients with predominant limbic symptoms (n=29/56) from those with peripheral nerve hyperexcitability (PNH; n=27/56). In the limbic-prominent group, limbic features were either isolated (LE/-; 18/56, 32.1%), or combined with extralimbic symptoms (LE/+; 11/56, 19.6%). Those with PNH were separated in one group with severe PNH and extralimbic involvement (PNH/+; 16/56, 28.6%), resembling historical MoS descriptions; and one group with milder and usually isolated PNH (PNH/-; 11/56, 19.6%). LE/- and LE/+ patients shared immunogenetic characteristics demonstrating a homogeneous entity. HLA-DRB1*11:01 was carried more frequently than in healthy controls only by patients with LE (94.1% vs 18.3%; p=1.3×10-10). Patients with LE also had serum titres (median 1:40 960) and rates of cerebrospinal fluid positivity (93.1%) higher than the other groups (p<0.05). Conversely, DRB1*11:01 association was absent in PNH/+ patients, but only they had malignant thymoma (87.5%), serum antibodies against leucine-rich glioma-inactivated 1 protein (66.7%) and against netrin-1 receptor deleted in colorectal carcinoma (53.8%), and myasthenia gravis (50.0%). INTERPRETATION: Symptoms' distribution supports specific clinical phenotypes without overlap between LE and MoS. The distinct immunogenetic characteristics shared by all patients with LE and the particular oncological and autoimmune associations of MoS suggest two very different aetiopathogenesis.


Asunto(s)
Autoanticuerpos/inmunología , Síndrome de Isaacs/fisiopatología , Encefalitis Límbica/fisiopatología , Proteínas de la Membrana/inmunología , Miocimia/fisiopatología , Proteínas del Tejido Nervioso/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Ataxia/fisiopatología , Análisis por Conglomerados , Receptor DCC/inmunología , Epilepsia del Lóbulo Temporal/fisiopatología , Función Ejecutiva/fisiología , Femenino , Antígenos HLA/genética , Humanos , Péptidos y Proteínas de Señalización Intracelular/inmunología , Síndrome de Isaacs/genética , Síndrome de Isaacs/inmunología , Encefalitis Límbica/genética , Encefalitis Límbica/inmunología , Masculino , Trastornos de la Memoria/fisiopatología , Persona de Mediana Edad , Miocimia/genética , Miocimia/inmunología , Fenotipo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA